Serum enzymes in disease. XI. Glycolytic and oxidative enzymes and transaminases in patients with cancer of the lung

The value of tumour markers in lung cancer

“…It was evident that in the 41 patients with SCLC, the median values of AP, GGT and AST were significantly elevated in those patients with extensive disease compared to those with limited disease. The levels of GGT, alkaline phosphatase and oxidative liver enzymes have been observed previously to rise at a relatively late stage of tumour dissemination (West et al, 1962;Neville & Cooper, 1976).…”

“…x2=2.5, P>0.2 Albumin (g l-1) Normal < 35 13 (93%) 22 (85%) 17 (59%) 1 (7%) 4 (15%) 12 (41%) Fisher's exact test, P< 0.03 x2 =10.72, P<0.005. NSCLC were increased at 156.61Ul 1 and 173.51Ul1 respectively, but measurement of the glycolytic enzyme did not differentiate between the type or stage of lung cancer. In an earlier report (West et al, 1962) 72% of 126 patients with lung cancer had elevated serum levels of PHI with higher values occurring in those with distant metastasis. Bodansky (1954) had previously observed a close correlation of serum PHI and the presence of bone and hepatic metastases in carcinoma breast.…”

“…Elevation of phosphohexose isomerase (PHI) and circulating immune complexes (CC) have been demonstrated in lung cancer (West et al, 1962;Schwartz et al, 1985). PHI is widely distributed in human tissue, and is a glycolytic enzyme abundantly found in liver and skeletal muscle.…”

“…PHI is widely distributed in human tissue, and is a glycolytic enzyme abundantly found in liver and skeletal muscle. West et al (1962) reported raised levels of PHI in 72% of 126 patients with lung cancer, with lower values in patients without distant metastases and highest values in those with hepatic metastases documented at autopsy. Schwartz et al (1985) stated that PHI in SCLC had the highest values in localised disease and suggested that PHI may be a useful marker in detecting early lung cancer.…”